2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8).
暂无分享,去创建一个
Jackson T. Wright | S. Oparil | W. Cushman | Sidney C. Smith | L. Svetkey | D. Lackland | R. Townsend | A. Narva | J. Handler | T. Mackenzie | S. Taler | M. LeFevre | B. Carter | P. James | C. Dennison-Himmelfarb | O. Ogedegbe | E. Ortiz | J. Wright
[1] Janusz Wnek,et al. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, Circulation.
[2] M. Lauer,et al. Refocusing the agenda on cardiovascular guidelines: an announcement from the National Heart, Lung, and Blood Institute. , 2013, Journal of the American College of Cardiology.
[3] M. Lauer,et al. Refocusing the agenda on cardiovascular guidelines: an announcement from the National Heart, Lung, and Blood Institute. , 2013, Circulation.
[4] A. Arboix,et al. Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial , 2013 .
[5] Jeroen J. Bax,et al. 2007 ESH-ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). , 2007, Blood pressure.
[6] Michael Böhm,et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). , 2007, Journal of hypertension.
[7] M. Jessup,et al. The next steps in developing clinical practice guidelines for prevention. , 2013, Journal of the American College of Cardiology.
[8] V. Basevi. Standards of Medical Care in Diabetes—2013 , 2012, Diabetes Care.
[9] David C. Wheeler,et al. Notice , 2012, Kidney International Supplements.
[10] S. Greenfield,et al. Clinical practice guidelines we can trust , 2011 .
[11] Laura A. Levit,et al. Finding what works in health care : standards for systematic reviews , 2011 .
[12] S. Nesbitt,et al. Management of high blood pressure in Blacks: an update of the International Society on Hypertension in Blacks consensus statement. , 2010, Hypertension.
[13] T. Ogihara,et al. Target Blood Pressure for Treatment of Isolated Systolic Hypertension in the Elderly: Valsartan in Elderly Isolated Systolic Hypertension Study , 2010, Hypertension.
[14] Kevin A Peterson,et al. Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus , 2011 .
[15] W. Elliott. Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial , 2010 .
[16] J. Staessen,et al. Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial , 2009, The Lancet.
[17] 石井當男. Principal Results of the Japanese Trial to Assess Optimal Systolic Blood Pressure in Elderly Hypertensive Patients (JATOS) , 2008, Hypertension Research.
[18] Li-sheng Liu,et al. Treatment of hypertension in patients 80 years of age or older. , 2008, The New England journal of medicine.
[19] S. Yusuf,et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. , 2008, The New England journal of medicine.
[20] B. Davis,et al. Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). , 2008, Archives of internal medicine.
[21] Anushka Patel,et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial , 2007, The Lancet.
[22] Chia-Chien Hsu,et al. The Delphi Technique: Making Sense of Consensus , 2007 .
[23] A. Dominiczak,et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) , 2007, European heart journal.
[24] B. Davis,et al. Clinical Events in High-Risk Hypertensive Patients Randomly Assigned to Calcium Channel Blocker Versus Angiotensin-Converting Enzyme Inhibitor in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial , 2006, Hypertension.
[25] T. Ogihara,et al. The Japanese Trial to Assess Optimal Systolic Blood Pressure in Elderly Hypertensive Patients (JATOS): Protocol, Patient Characteristics, and Blood Pressure during the First 12 Months , 2005, Hypertension Research.
[26] G. Remuzzi,et al. Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial , 2005, The Lancet.
[27] A. Dhar,et al. National Institute for Health and Clinical Excellence , 2005 .
[28] Peter Littlejohns,et al. NICE clinical guidelines: Maybe health economists should participate in guideline development , 2004, BMJ : British Medical Journal.
[29] L. Wilkins. Diuretic Versus &agr;-Blocker as First-Step Antihypertensive Therapy: Final Results From the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) , 2003 .
[30] N. Hollenberg. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. , 2003, Current hypertension reports.
[31] Daniel W. Jones,et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. , 2003, JAMA.
[32] C. E. Machado,et al. Diuretic versus alpha-blocker as first-step antihypertensive therapy: final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). , 1998, Hypertension.
[33] B. Davis,et al. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). , 2002, JAMA.
[34] Tom Greene,et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. , 2002, JAMA.
[35] M. Nieminen,et al. For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .
[36] B. Brenner,et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy , 2002 .
[37] B. Brenner,et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. , 2001, The New England journal of medicine.
[38] E. Lewis,et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. , 2001, The New England journal of medicine.
[39] C. Bulpitt,et al. Effects of Calcium-Channel Blockade in Older Patients with Diabetes and Systolic Hypertension , 1999 .
[40] Philip D. Harvey,et al. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 , 1998, BMJ.
[41] Joël Ménard,et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial , 1998, The Lancet.
[42] Jan A Staessen,et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension , 1997, The Lancet.
[43] B. Davis,et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. , 1996, JAMA.
[44] G. Beck,et al. The Effects of Dietary Protein Restriction and Blood-Pressure Control on the Progression of Chronic Renal Disease , 1994 .
[45] A. López,et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. , 1994, The New England journal of medicine.
[46] A Fournier,et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. , 1994, The New England journal of medicine.
[47] R. Bain,et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. , 1993 .
[48] R. Bain,et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. , 1993, The New England journal of medicine.
[49] G. Striker. Modification of diet in renal disease. , 1992, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[51] A. Doyle,et al. The Australian Therapeutic Trial in Mild Hypertension. , 1982, Nephron.
[52] J. Abernethy. The Australian therapeutic trial in mild hypertension. , 1984, Hypertension.
[53] Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. , 1970, JAMA.